Massachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it matters: Diabetes patients are often paying hundreds of dollars a month or more for life-saving medicine when the costs of production remain largely unchanged, Attorney General Andrea Campbell's lawsuit says. - Those price increases can cause diabetics to forego insulin shots or find workarounds that endanger them, the lawsuit argues.
Driving the news: Campbell's office filed a lawsuit this week in Suffolk Superior Court against drugmakers and the middlemen, known as pharmacy benefit managers, accusing them of defrauding diabetes patients through an insulin pricing scheme. - The lawsuit names drugmakers Eli Lilly, Novo Nordisk and Sanofi, as well as PBMs Optum Rx, Express Scripts, CVS Caremark and affiliated companies.
The other side: CVS Caremark told Axios that drugmakers "alone are responsible" for setting their products' prices. The company also said its ReducedRx program offers insulin for $25. - Sanofi said the average net price of its insulins has declined but that savings negotiated by PBMs and insurers through rebates "are not consistently passed through to patients."
- Other companies named in the suit did not respond to Axios' requests for comment.
By the numbers: One 2018 study suggests making a year's supply of insulin costs anywhere from $48-$134 per person. - Massachusetts has some 500,000 diabetes patients and 1.8 million pre-diabetic patients, many of whom rely on insulin and are paying hundreds monthly for the list prices, the lawsuit says.
The big picture: New York and Minnesota have successfully gotten drugmakers to cap their prices to $35 a month in legal settlements. - The Federal Trade Commission in September sued three major PBMs and affiliated companies, accusing them of engaging in anticompetitive and unfair rebating practices that inflate insulin prices.
- Express Scripts previously sued the FTC over a July report purporting to show how PBMs manipulate the market at the expense of patients.
Between the lines: Massachusetts recently enacted a law that caps name-brand drugs for certain illnesses, including diabetes, at $25 a month, among other changes. - But Campbell's lawsuit targets what she described as the source of the problem: the pricing agreements secretly agreed upon by drugmakers and PBMs.
Keep reading: Inside the lawsuit
|